



## Leap Therapeutics to Present at the ESMO 2021 Virtual Congress

July 26, 2021

CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's Ltd.'s anti-PD-1 antibody, with or without chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress, being held virtually on September 16-21, 2021. The Company plans to host a conference call on Thursday, September 16, 2021 to further discuss the data.

"We are pleased to have the opportunity to share initial data from the DisTinGuish study at ESMO in September," said Douglas E. Onsi, President and Chief Executive Officer of Leap. "We are encouraged by the potential DKN-01 has to improve response rates as part of first-line therapy for gastric and gastroesophageal junction cancer patients, particularly those patients whose tumors express high levels of DKK1, and look forward to providing additional details at this year's congress."

### **Leap Presentation Details:**

**Title:** DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial

**Abstract Number:** 2218

**Session type:** E-Poster Presentation

**Presenter:** Samuel J. Klempner, Harvard Medical School

**Date and time:** Thursday, September 16, 2021; 2:30 a.m. ET

### **About the DisTinGuish Study**

The DisTinGuish study ([NCT04363801](https://clinicaltrials.gov/ct2/show/study/NCT04363801)) is a Phase 2a, non-randomized, open-label, multicenter study of DKN-01 in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, with or without chemotherapy as first-line or second-line therapy in adult patients with inoperable, locally advanced gastric or gastroesophageal junction cancer G/GEJ adenocarcinoma. The study, which is being conducted in two parts in the United States and the Republic of Korea, completed enrollment of 25 patients with first-line G/GEJ cancer in April 2021 and will enroll up to 48 patients with second-line G/GEJ cancer whose tumors express high levels of DKK1. Leap is conducting this combination study as part of an exclusive option and license agreement with BeiGene for the development of DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

### **About Leap Therapeutics**

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit <http://www.leaptx.com> or view our public filings with the SEC that are available via EDGAR at <http://www.sec.gov> or via <https://investors.leaptx.com/>.

RNAscope® is a registered trademark of Advanced Cell Diagnostics, Inc., Newark, CA, USA.

### **FORWARD-LOOKING STATEMENTS**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include Leap's expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in future studies, potential for the receipt of future option exercise, milestone, or royalty payments from BeiGene, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19 related issues; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap Therapeutics' periodic filings with the SEC, including Leap's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC on March 12, 2021 and as may be updated by Leap's Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statement contained in this release speaks only as of its date. Leap undertakes no obligation to update any forward-looking statement contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

### **CONTACT:**

Douglas E. Onsi

President & Chief Executive Officer  
Leap Therapeutics, Inc.  
617-714-0360  
[donsi@leaptx.com](mailto:donsi@leaptx.com)

Heather Savelle  
Investor Relations  
Argot Partners  
212-600-1902  
[heather@argotpartners.com](mailto:heather@argotpartners.com)



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-the-esmo-2021-virtual-congress-301340715.html>

SOURCE Leap Therapeutics, Inc.